SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) today announced that Michael A. Martino, President and Chief Executive Officer, will participate on the �Enhancing Cancer Therapy: Safer and Better� panel on December 13, 4:30 P.M. ET, as part of the 2006 RBC Capital Markets Healthcare Conference, being held at the Westin New York at Times Square in New York City. A live webcast of the panel discussion will be available on the Sonus web site at www.sonuspharma.com/events.html. The webcast will also be archived at the same link for 30 days after the conference. The Company�s lead product candidate, TOCOSOL� Paclitaxel, is a novel, proprietary formulation of the widely prescribed anti-cancer drug, paclitaxel. TOCOSOL Paclitaxel is currently in a Phase 3 pivotal trial in metastatic breast cancer. Patient enrollment in that trial was completed in November 2006. The New Drug Application submission for TOCOSOL Paclitaxel is targeted for the end of 2007. Formulated with Sonus' vitamin E-based TOCOSOL technology, TOCOSOL Paclitaxel may have the ability to offer a better tolerated, easier to use and potentially safer and more effective alternative paclitaxel therapy for cancer patients. About Sonus Pharmaceuticals, Inc. Headquartered near Seattle, Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide improved efficacy, safety and tolerability, and are more convenient to use. In addition to the continuing development of TOCOSOL Paclitaxel, Sonus initiated the Phase 1 clinical program for its second oncology product candidate, TOCOSOL Camptothecin, in September 2006. Utilizing the Company�s TOCOSOL technology, TOCOSOL Camptothecin is designed to improve the treatment and therapeutic outcomes in patients treated with camptothecin-based drugs. Preclinical data suggest that TOCOSOL Camptothecin may be more efficacious and better tolerated than irinotecan, a marketed camptothecin analog. For additional information on Sonus, including news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals� filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2005 and Quarterly Report on Form 10-Q for the third quarter of 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company�s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.